Arcus Biosciences, Inc. (RCUS)
25.15
-0.25
(-0.98%)
USD |
NYSE |
Dec 11, 16:00
25.09
-0.06
(-0.24%)
After-Hours: 20:00
Arcus Biosciences Cash from Investing (Quarterly): 79.00M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Actinium Pharmaceuticals, Inc. | 0.00 |
| Apyx Medical Corp. | -0.519M |
| Gilead Sciences, Inc. | -427.00M |
| Merck & Co., Inc. | -283.00M |
| Karyopharm Therapeutics, Inc. | 4.805M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -97.00M |
| Cash from Financing (Quarterly) | 8.00M |
| Free Cash Flow | -464.00M |
| Free Cash Flow Per Share (Quarterly) | -0.9108 |
| Free Cash Flow to Equity (Quarterly) | -99.00M |
| Free Cash Flow to Firm (Quarterly) | -94.00M |
| Free Cash Flow Yield | -18.31% |